National Institutes of Health Translational Research Interest Group
NIH Translational Research Interest Group Lecture Series 

Translational Research Interest Group 

Our Theme: Bench to Bedside & Back 

The purpose of the Translational Research Interest Group (TRIG) is to bring together physician scientists and basic research scientists to discuss efficient ways of accelerating the application of biomedical discoveries to clinical practice, ultimately for the benefit of patients.  Conversely, it is also aimed to promote the translation of clinical observations into the development of improved preclinical study strategies and disease models.  The TRIG coordinates seminars, forums and symposia to help bridge the gap between laboratory research and clinical applications.  It also suggests topics and speakers for the Annual NIH Research Festivals, and nominates speakers for the NIH Wednesday Afternoon Lecture Series.

NIH intramural and extramural scientists are invited to become members of the TRIG.  The invitation to join the TRIG is extended to staffs at the Food and Drug Administration and other Federal Government Agencies, and scientists from the extramural research community outside of Government.  Please join our listserv and also add your name to our member list

TRIG events are announced through the listserv and this website.  The TRIG co-chairs are Vincent Manganiello and George Uhl.

Visit "Meetings and Seminars" for complete schedule of the TRIG-hosted events and abstracts of lectures.








Events in 2013-2014:

Lecture hosted by the NIH Translational Research Interest Group
June 12, 2014 (Thursday) 1-2 pm.
Bldg. 10 (Clinical Research Center) Lipsett Amphitheater


Kapil Bharti, PhD
Earl Stadtman Tenure-Track Investigator
Head, Unit on Ocular and Stem Cell Translational Research

Title: Induced to Cure: Engineering iPS Cell-derived RPE Scaffolds to Treat Degenerative Eye Diseases

Description: The recent success with embryonic stem (ES) cell-derived retinal pigment epithelium (RPE) has provided hope for a treatment for degenerative eye diseases. Induced pluripotent stem (iPS) cells are an alternate and an autologous source of stem cells with potentially fewer immune-challenges as compared to ES cells. Using a developmentally-guided differentiation protocol we have developed fully polarized RPE tissue from iPS cells. The RPE monolayer along with its secreted ECM and the scaffold form a tissue that well mimics the native tissue. This tissue has been functionally authenticated in vitro for its ability to perform several key RPE functions and is being tested in animal models. We have begun manufacturing for a Phase I Investigational New Drug (IND) to transplant autologous iPS cell-derived RPE in patients in advanced Geographic Atrophy stage of age-related macular degeneration (AMD), one of the leading blinding diseases in the US. We propose to develop the National Institutes of Health Clinical Center as an “alpha-stem cell clinic” with the capability to recruit patients, manufacture clinical-grade autologous iPS cell-derived RPE tissue, perform transplantation, do patient care, and be able to transfer technology to academic and private sectors. We suggest that our open access model with complete access to the entire IND package will reduce redundant efforts in the field, foster public-private partnerships, and help move the ocular regenerative medicine field forward.





NIH Translational Research Interest Group Lecture Series

Forum hosted by the NIH Translational Research Interest Group
May 8, 2014 (Thursday) 1-3 pm, Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Title:Translational Research in the NHLBI Intramural Program

Michael Sack, M.D., Ph.D.

Chief, Cardiovascular Pullmonary Branch, NHLBI


Manfred Boehm, M.D.

Senior Investigator, Center for Molecular Medicine, NHLBI

Title: Vascular remodeling in mice and man.

Description: Three topics will be discussed:
1) the role of endothelial to mesenchymal transition during vein graft remodeling in a murine model.
2) the identification and elucidation of two rare genetic diseases.

ACDC (Arterial calcification due to deficiency of CD73): from genotype to disease mechanism and therapy.
DADA2 (Deficiency of ADA2): the role of monocyte endothelial cell interaction in children with early onset strokes.

Adrian Wiestner, M.D., Ph.D.
Senior Investigator, Hematology Branch, NHLBI

Title: Targeting B-cell receptor signaling in lymphoma and leukemia

Description: The B-cell receptor (BCR) is essential for normal B-cell development and maturation.  In an increasing number of B-cell malignancies, BCR signaling is implicated as a pivotal pathway in tumorigenesis.  Chronic lymphocytic leukemia has been recognized for decades as a malignancy of auto-reactive B-cells and its clinical course is in part determined by the differential response of the malignant cells to BCR activation. Recently, a role for BCR signaling has been suggested in mantle cell lymphoma (MCL).  Ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase effectively blocks BCR signaling and induces high rates of response in both CLL and MCL.  I will discuss ex-vivo analyses of patient samples that support the importance of BCR signaling in CLL and MCL and will present results from our ongoing clinical trial with ibrutinib in CLL.

April 3, 2014 (Thursday) 1-2 pm, Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Kyung S. Lee, Ph.D.
Senior Investigator, Laboratory of Metabolism, National Cancer Institute, NIH 
Title: Polo-like Kinase 1 (Plk1) in Mitotic Control and Anti-cancer Therapy 

NIH Translational Research Interest Group Lecture Series

March 13, 2014 (Thursday) 1-2 pm, Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Jurgen Wess, Ph.D.
Chief, Molecular Signaling Section, Lab. of Bioorganic Chemistry, NIDDK
Title: Studies with muscarinic acetylcholine receptor mutant mice: Implications for the treatment of type 2 diabetes and obesity.

NIH Translational Research Interest Group Lecture Series

February 13, 2014 (Thursday) 1-2 pm, Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Susan E. Bates M.D.
Head, Molecular Therapeutics Section, Developmental Therapeutics Branch, NCI
Title: Past Present Future: The Evolution of Epigenetic Therapies in Cancer.

NIH Translational Research Interest Group Lecture Series

January 9, 2014 (Thursday) 1-2 p.m., NIH Bldg 10 (Clinical Research Center)  Lipsett Amphitheater 
Frederick W. Miller, M.D., Ph.D
Chief, Environmental Autoimmunity Group, Program of Clinical Research, NIEHS

Title:Autoimmune Disease Phenotypes: Touchstones for Identifying Genetic and Environmental Risk Factors

NIH Translational Research Interest Group Lecture Series

September 12, 2013 (Thursday) 1-2 p.m., Bldg. 50 Lobby Rm 1227/1233, NIH Campus
Shihui Liu, M.D., Ph.D.
Staff Scientist, Laboratory of Parasitic Diseases, NIAID
Title: Treating solid tumors with tumor-associated protease-activated anthrax toxins

NIH Translational Research Interest Group Lecture Series

November 14, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Jay Chung, M.D., Ph.D.
Chief, Laboratory of Obesity and Aging Research
Title: Taking lessons from red wine and resveratrol into the clinic

NIH Translational Research Interest Group Lecture Series

September 12, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Stewart Levine, M.D.
Senior Investigator, Laboratory of Asthma and Lung Inflammation, NHLBI
Title: From Bedside to Bench to Clinical Trials: Identifying New Treatments for Asthma






























































Events in 2012-2013:

NIH Translational Research Interest Group Lecture Series
June 13, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Ena Wang, M.D.
Director of Molecular Science, Infectious Diseases and Immunogenetics Section
Department of Transfusion Medicine, NIH Clinical Center
“Genetic Inference about Cancer Immune Responsiveness”



Forum on “Immunotoxins for Cancer Treatment: From Design to Clinical Success

May 9, 2013 (Thursday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Ira Pastan, M.D.
NIH Distinguished Investigator; Institute of Medicine Member; Co-Chief, Laboratory of Molecular Biology, National Cancer Institute (NCI)
“Introduction to Recombinant Immunotoxins”

Robert J. Kreitman, M.D.
Head, Clinical Immunotherapy Section, Laboratory of Molecular Biology; Senior Investigator, NCI
“Treatment of Refractory Hairy Cell Leukemia with Moxetumomab pasudotox”

Alan S. Wayne, M.D.
Head, Hematologic Diseases Section; Senior Clinician, Pediatric Oncology Branch, NCI
“Treatment of Refractory Acute Lymphoblastic Leukemia in Children with Moxetumomab pasudotox”



Raffit Hassan, M.D.
Head, Solid Tumor Immunotherapy Section, Laboratory of Molecular Biology; Senior Investigator, NCI
“Treatment of Mesothelioma with Immunotoxin SS1P”

Ira Pastan, M.D.
“Future Directions”


























NIH Translational Research Interest Group Lecture Series
May 2, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Rajesh Ranganathan, Ph.D.
Director, Office of Translational Research, National Institute of Neurological Disorders and Stroke
“NINDS Accelerates Therapeutic and Device Discovery and Development”

NIH Translational Research Interest Group Lecture Series
April 18, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater


























Bibi Bielekova, M.D.
Chief, Neuroimmunological Diseases Unit, Neuroimmunology Branch, NINDS
“Can implementation of systems biology into clinical trials accelerate understanding of complex disease? Lessons from Multiple Sclerosis”

NIH Translational Research Interest Group Lecture Series
March 14, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Crystal L. Mackall, M.D.
Chief, Pediatric Oncology Branch; Head, Immunology Section
Center for Cancer Research, NCI
“Developing Immunotherapies for Childhood Cancer”

NIH Translational Research Interest Group Lecture Series
February 14, 2013 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Ludmila Prokunina-Olsson, Ph.D.
Investigator, Laboratory of Translational Genomics
Division of Cancer Epidemiology and Genetics, NCI
“Identification and characterization of a novel human interferon, IFNL4, and its role in human evolution and disease”

NIH Translational Research Interest Group Lecture Series
January 10, 2013 (Thursday) 1-2 p.m., Bldg. 10 Room 2-C116

Gustavo Pacheco-Rodriguez, Ph.D.
Staff Scientist, Cardiovascular and Pulmonary Branch, NHLBI
“Molecular and Cellular Mechanisms of Lymphangioleiomyomatosis (LAM)”

NIH Translational Research Interest Group Lecture Series
December 13, 2012 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Phil Skolnick, PhD, DSc (hon.)
Director, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, NIDA
“Developing Drugs to Treat Substance Use Disorders (SUDs): Why Haven't We Been More Successful?”
NIH Translational Research Interest Group Lecture Series
November 8, 2012 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

George Kunos, MD, PhD
Scientific Director of Intramural Research, National Institute on Alcohol Abuse and Alcoholism (NIAAA)
“The peripheral endocannabinoid/CB1 receptor system is a novel therapeutic target for obesity, diabetes and fatty liver disease”
NIH Translational Research Interest Group Lecture Series
October 25, 2012 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater

Robert A. Star, MD
Director, Division of Kidney, Urologic and Hematologic Diseases, NIDDK
Senior Investigator and Chief, Renal Diagnostics and Therapeutics Unit, NIDDK
“Sepsis and Acute Kidney Injury: Kidney as amplifier and target”

2012 NIH Research Festival
October 11, 2012 (Thursday) 12:00 p.m.-2:00 p.m.
Natcher Conference Center Room E1/E2

Symposium Session IV
“Common Molecular Mechanisms Underlying Pathogenesis and Treatment of Human Diseases”
Co-Chairs: Minkyung (Min) Song, PhD, NCI, and Joel Moss, MD, PhD, NHLBI

Matthew Alkaitis, FARE Award Winner, NIAID
“Malaria Infection Depletes Erythrocyte Tetrahydrobiopterin, an Essential Cofactor for Nitric Oxide Synthesis"
Joel Moss, MD, PhD, NHLBI
“Mammalian Target of Rapamycin (mTOR) as a Target for Therapeutic Intervention in Diverse Diseases”
Ludmila Prokunina-Olsson, PhD, NCI
“From Cancer Genetics to Translational Genomics: Genetic and Functional Association of Prostate Stem Cell Antigen (PSCA) Gene with Several Cancers”
Gregory Kato, MD, NHLBI
“Pleiotropic Effects of Intravascular Hemolysis upon Vascular Homeostasis”
Emily Y. Chew, MD, NEI
“Treatment for Age-Related Macular Degeneration by Targeting Diverse Pathogenic Pathways”
David S. Goldstein, MD, PhD, NINDS
“Willie Sutton's Getaway Car and the Pathogenesis of Lewy Body Diseases”

2012 NIH Research Festival
October 10, 2012 (Wednesday) 10:00 a.m.-12:00 p.m.
Natcher Conference Center Room F
Symposium Session II
“Health Disparities: Advances in Translational, Clinical, and Population Sciences”
Co-Chairs: Anil Wali, PhD, NCI, and Jeffrey Kopp, MD, NIDDK


Cheryl Winkler, PhD, NCI
“Identification of APOL1 genetic variation explains much of the increased chronic kidney disease characteristic of African Americans”
Stefan Ambs, PhD, NCI
“A prognostic metabolome signature in breast tumors is linked to a distinct DNA methylation pattern in African-American and European-American patients”
Kevin Gardner, MD, PhD, NCI/CCR
"Molecular Linkages between Race, Obesity and Triple-negative Breast Cancer"
Charles Rotimi, PhD, NHGRI
“Ethnic Differences in lipid distribution: Implications for disease risk and response to treatment”
Cristina Rabadán-Diehl, PhD, MPH, NHLBI
“Health Disparities in Cardiovascular Disease: A Global Health Perspective”
NIH Translational Research Interest Group Lecture Series









September 13, 2012 (Thursday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Forum on “Discovery and Development of Therapeutic Candidates for Rare and Neglected Diseases at NIH”
John McKew, Ph.D.
Chief of the Therapeutic Development Branch and Director of Chemistry, NIH Center for Translational Therapeutics, National Center for Advancing Translational Sciences (NCATS)
“Public Private Partnerships to Advance Therapeutics for Rare and Neglected Diseases”

Marjan Huizing, Ph.D.
Head, Cell Biology of Metabolic Disorders Unit, Medical Genetics Branch, NHGRI
“N-acetylmannosamine (ManNAc) as a Therapy for Disorders of Hyposialylation”
Nuria Carrillo, M.D.
Staff Clinician, Therapeutics for Rare & Neglected Diseases (TRND), NCATS
“Translating ManNAc into a Therapy for Patients with Hereditary Inclusion Body Myopathy (HIBM)”








































National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892.
  Department of Health and Human Services - Government made easy